264 related articles for article (PubMed ID: 22189143)
1. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
Yang Y; Zhou Z; He S; Fan T; Jin Y; Zhu X; Chen C; Zhang ZR; Huang Y
Biomaterials; 2012 Mar; 33(7):2260-71. PubMed ID: 22189143
[TBL] [Abstract][Full Text] [Related]
2. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
3. Targeting prostate carcinoma by G3-C12 peptide conjugated N-(2-hydroxypropyl)methacrylamide copolymers.
Yang Y; Li L; Zhou Z; Yang Q; Liu C; Huang Y
Mol Pharm; 2014 Oct; 11(10):3251-60. PubMed ID: 24955652
[TBL] [Abstract][Full Text] [Related]
4. G3-C12 Peptide Reverses Galectin-3 from Foe to Friend for Active Targeting Cancer Treatment.
Sun W; Li L; Yang Q; Shan W; Zhang Z; Huang Y
Mol Pharm; 2015 Nov; 12(11):4124-36. PubMed ID: 26393405
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Xiang Q; Yang Y; Zhou Z; Zhou D; Jin Y; Zhang Z; Huang Y
Eur J Pharm Biopharm; 2012 Feb; 80(2):379-86. PubMed ID: 22101181
[TBL] [Abstract][Full Text] [Related]
6. Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12.
Sun W; Li L; Li LJ; Yang QQ; Zhang ZR; Huang Y
Acta Pharmacol Sin; 2017 Jun; 38(6):806-822. PubMed ID: 28065935
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable brush-type copolymer modified with targeting peptide as a nanoscopic platform for targeting drug delivery to treat castration-resistant prostate cancer.
Liu T; Huang Q
Int J Pharm; 2016 Sep; 511(2):1002-11. PubMed ID: 27521701
[TBL] [Abstract][Full Text] [Related]
9. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
11. In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates.
Yuan F; Qin X; Zhou D; Xiang QY; Wang MT; Zhang ZR; Huang Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):770-6. PubMed ID: 18656539
[TBL] [Abstract][Full Text] [Related]
12. [In vitro release study, in vivo evaluation of biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates].
Yuan F; Zhang ZR; Yang YX; Huang Y
Yao Xue Xue Bao; 2008 Nov; 43(11):1152-6. PubMed ID: 19239037
[TBL] [Abstract][Full Text] [Related]
13. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
14. Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy.
Xiang Y; Chen L; Zhou R; Huang Y
Int J Pharm; 2019 Oct; 570():118668. PubMed ID: 31494237
[TBL] [Abstract][Full Text] [Related]
15. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor angiogenic vasculature using polymer-RGD conjugates.
Mitra A; Mulholland J; Nan A; McNeill E; Ghandehari H; Line BR
J Control Release; 2005 Jan; 102(1):191-201. PubMed ID: 15653145
[TBL] [Abstract][Full Text] [Related]
17. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657
[TBL] [Abstract][Full Text] [Related]
18. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.
Liu J; Kopecková P; Bühler P; Wolf P; Pan H; Bauer H; Elsässer-Beile U; Kopecek J
Mol Pharm; 2009; 6(3):959-70. PubMed ID: 19344119
[TBL] [Abstract][Full Text] [Related]
19. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
20. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]